MINNEAPOLIS, Dec. 3 /PRNewswire/ -- AGA Medical Corporation announced today that it received European CE Mark (Conformite Europeenne) approval for its AMPLATZER(R) Cardiac Plug (ACP). The ACP provides an innovative, minimally invasive solution for closing cardiac structures not involving the septal wall. One such intended use will be for the non-surgical occlusion of the left atrial appendage.
"The ACP is an important addition to the interventional tools we have for structural heart repair. The design and conformability of the device as well as its ease of deliverability will allow us to effectively occlude challenging anatomy such as the left atrial appendage," said Bernhard Meier, MD, FACC, FESC, professor and chairman of cardiology, University Hospital, Bern, Switzerland. "Scientific data suggests a strong link between atrial fibrillation and formation of thrombus in the left atrial appendage, which can increase the risk of stroke to 5 percent per year. Physicians have limited options to minimize stroke risk other than anticoagulants which are often associated with adverse side effects."
Made of flexible braided Nitinol mesh, the ACP is designed to provide occlusion with full cross-sectional coverage. The ACP self-orients to the cardiac wall, covering the hole of the structure to be occluded. It leverages the proven microscrew technology platform used in all AGA Medical devices to provide physicians with simple, controlled and precise delivery. This allows the ACP to be recaptured and repositioned if necessary, ensuring a customized delivery and fit for each patient's unique anatomic structure.
"Receiving CE Mark approval for the ACP is a significant milestone for AGA
Medical," said John Barr, President and CEO, AGA Medical Corporation. "This
device exemplifies our commitment to making structural heart devices that are
clinically relevant, safe and easy to use. With approximately 5 percent of the
|SOURCE AGA Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved